Loading…
No business profile yet.
Size Sichuan Neautus Traditional Chinese (2206.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $779M, the 641st largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$85.40 on 18 Nov 2026.
Growth Revenue grew 7.0% over the last twelve months (peer median +5.6%); the operating margin is 8.2% (peer median 12.0%).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | HK$1.44B | HK$1.35B | HK$1.26B | HK$903M |
| Revenue growth | — | +7% | +7% | +40% | — |
| Gross profit | n/a | HK$263M | HK$221M | HK$224M | HK$183M |
| EBITDA | n/a | HK$139M | HK$122M | HK$138M | HK$111M |
| Net income | n/a | HK$115M | HK$96.6M | HK$115M | HK$90.0M |
| Free cash flow | n/a | HK$91.2M | -HK$17.5M | HK$104M | HK$5.68M |
| Capital expenditure | n/a | HK$13.5M | HK$24.5M | HK$20.0M | HK$21.1M |
| Total debt | n/a | HK$241M | HK$173M | HK$132M | HK$178M |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2206.HK | Peer median | Rank in peer set |
|---|---|---|---|
| Revenue growth (TTM) | +7.0% | +5.6% | 10th highest of 19 |
| Operating margin | 8.2% | 12.0% | 9th lowest of 19 |
| Net debt / EBITDA | 0.3× | -0.5× | 4th most indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sichuan Neautus Traditional Chinese 2206.HK | Hong Kong | $779M | n/a | +7% | 8% | n/a | n/a | n/a |
| Bliss GVS Pharma BLISSGVS.NS | India | $777M | +141% | +25% | 18% | 6.7× | 33.9% | +10.1% |
| Zhejiang Int'l 000411.SZ | China | $783M | -21% | +3% | 3% | 0.3× | n/a | n/a |
| Ardelyx ARDX | United States | $784M | -50% | +18% | -8% | 1.6× | n/a | n/a |
| Jinghua Pharmaceutical 002349.SZ | China | $785M | -8% | +2% | 20% | 3.1× | -2.5% | +2.6% |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $771M | -7% | -13% | 4% | 0.9× | -3.8% | -0.8% |
| Bambusa Therapeutics BBTX | United States | $791M | n/a | n/a | n/a | n/a | n/a | n/a |
| Ironwood Pharmaceuticals IRWD | United States | $791M | +22% | +18% | 63% | 2.6× | n/a | n/a |
| Lexicon Pharmaceuticals LXRX | United States | $766M | -22% | -46% | -147% | 16.7× | n/a | n/a |
| Knight Therapeutics GUD.TO | Canada | $792M | +41% | +36% | 6% | 1.8× | 6.6% | +17.7% |
| Katakura Industries 3001.T | Japan | $765M | +40% | -2% | 15% | 2.4× | 0.3% | +0.5% |
| Oric Pharmaceuticals ORIC | United States | $795M | -9% | n/a | n/a | n/a | n/a | n/a |
| Sanofi India SANOFI.NS | India | $797M | 0% | -6% | 26% | 4.1× | 16.3% | -8.7% |
| Rigel Pharmaceuticals RIGL | United States | $801M | +48% | +2% | 26% | 2.5× | 1.5% | +22.1% |
| Bide Pharmatech 688073.SS | China | $801M | +10% | +10% | 19% | 3.1× | 13.9% | +27.7% |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $755M | -20% | -25% | 2% | 2.5× | 13.5% | -0.2% |
| Suven Life Sciences SUVEN.NS | India | $803M | -1% | +55% | -4,452% | 789.4× | n/a | n/a |
| Collegium Pharmaceutical COLL | United States | $806M | -24% | +8% | 15% | 2.3× | -2.6% | +20.3% |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $752M | -7% | +8% | 10% | 5.3× | 9.4% | -1.4% |
| CARsgen Therapeutics 2171.HK | Hong Kong | $751M | -45% | +68% | -170% | 28.6× | n/a | n/a |
| Hygeia Healthcare 6078.HK | Hong Kong | $811M | -3% | +2% | 14% | 1.8× | 4.6% | +22.5% |